What are neurodegenerative diseases?

Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

Neurodegenerative diseases represent a group of disorders characterised by the progressive structural and functional degeneration of the central and peripheral nervous systems. They affect millions of people worldwide, especially the elderly population.

What are the symptoms of neurodegenerative disease?

The symptoms of neurodegenerative diseases vary, with some predominantly leading to problems with movement (ataxias, e.g. Parkinson’s), while others mainly cause problems with mental functioning (dementia, e.g. Alzheimer’s). Most neurodegenerative disorders develop at later life stages and lead to increased disability over time. They can affect many aspects of a person’s life, such as bladder and bowel function, blood pressure, breathing, heart function, memory and cognitive abilities, mobility and balance, mood, sleep, speech and swallowing.

What causes neurodegenerative diseases?

Neurodegenerative diseases occur when nerve cells in the brain or peripheral nervous system lose their function over time and ultimately die. Treatments may help relieve some of the physical or mental symptoms. However, there is currently no way to slow disease progression or cures. The risk of being affected by a neurodegenerative disease increases significantly with age.

The combination of genetics and environmental factors contributes to the risk of developing a neurodegenerative disease. Therefore, it is difficult to predict who will develop the disease. A person’s genetics might make them more susceptible to a certain neurodegenerative disease. But whether, when, and how severely the person is affected depends on environmental exposures throughout life.

What are the most common neurodegenerative diseases?

Alzheimer’s disease and are the most common neurodegenerative diseases, followed by , Huntington’s disease, and .

Alzheimer’s disease

Alzheimer’s disease (AD) is the most common cause of dementia accounting for 60-80% of cases. Dementia is a general term for memory loss and loss of other behavioural and cognitive abilities.

Genetic factors are known to be involved in all forms of AD. Variants in PSEN1, PSEN2 and APP lead to the autosomal dominant inherited early form of AD (disease onset <60 years). In families with affected individuals in at least three generations, ~60% of cases are caused by variants in the PSEN1 gene and ~20% by variants in the APP gene. Variants in the PSEN2 gene cause <5% of cases.

Symptoms can range from mild to severe, up to the inability to do activities of daily living. The most common type of AD affect people who are 65 and older (). Rarely, AD can develop in people <60 years (). Symptoms of young-onset AD develop between 30-60 years. The hallmark pathologies of AD are the accumulation of the protein beta-amyloid (plaques) in the brain and twisted strands of the protein tau (tangles) inside neurons.

Types of genetic testing for Alzheimer’s

Diagnostic testing

Recommended for patients who:

  • Have dementia and want to know if it is caused by Alzheimer’s
  • Have been diagnosed with Alzheimer’s and want to confirm the diagnosis
  • Developed Alzheimer’s at an earlier age (<60 years)

Predictive testing

Recommended for relatives of Alzheimer’s patients who:

  • Want to determine their carrier status (diagnostic testing detected variant in patient)
  • Have a strong family history of dementia suggesting a variant for inherited Alzheimer’s

Please note: To date, no treatment is available that can prevent or slow the progression of Alzheimer’s. A positive result has implications for the patient and their relatives, who may or may not want to know the result. Additionally, it cannot predict symptom onset. A negative result is quite common even with a very strong family history. This does not rule out the possibility of a genetic explanation for dementia. An inconclusive result may cause anxiety and uncertainty.

Parkinson’s disease

Parkinson’s disease (PD) affects predominately dopaminergic neurons in the brain area called substantia nigra, leading to low levels or missing dopamine in the brain and eventually resulting in neuronal impairment.

In about 5%–10% of patients with PD, pathogenic variants in DJ1, GBA, LRRK2, PINK1, PRKN, SNCA or VPS35 genes can be found. Late-onset PD (age >50 years) is associated with autosomal dominant variants in the LRRK2 or GBA genes, whereas young-onset PD (age <40 years) is caused by variants in the PRKN, PINK1, and DJ1 genes following an autosomal recessive inheritance.

Motor symptoms include tremor, bradykinesia, limb rigidity, gait and balance problems. Non-motor symptoms may include depression, constipation, sleep disturbances, loss of sense of smell and cognitive impairment. The disease is progressive and symptoms can vary for each patient.

Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a common neuromuscular disease that belongs to the group of motor neuron diseases. ALS is caused by degeneration of motor neurons leading to gradual muscle weakness and atrophy.

The majority of ALS cases occur sporadically with no associated risk factors and no family history. However, 5-10% of all ALS cases are familial. Variants in the C9ORF72 gene account for about 25-40% of all familial cases and a small percentage of sporadic cases. Another 12-20% of familial ALS result from variants in the SOD1 gene.

Early symptoms can be subtle and may include muscle weakness or stiffness. As the disease progresses, problems with moving, swallowing, speaking or forming words, and breathing may occur. Eventually, the ability to initiate and control voluntary muscle movements is lost. Most ALS patients die from respiratory failure, usually within 3-5 years after symptom onset. However, about 10% of patients survive >10 years.

Huntington’s disease

Huntington’s disease (HD) is an inherited neurological disorder characterised by involuntary movements, severe emotional disturbance and cognitive decline.

HD is caused by a CAG repeat expansion in the HTT gene. In the normal HTT gene, this sequence is repeated between 11-29 times. In the mutant gene, the repeat occurs ≥40 times. As a result, huntingtin protein clumps in the brain leading to neuronal loss, especially in the basal ganglia and cortex. HD is inherited in an autosomal dominant pattern.

Symptoms develop between 30-50 years, but may also occur as early as age 2 or as late as 80. The main characteristic of HD is uncontrolled movement. Additionally, a decline in thinking and reasoning skills, including memory, concentration, judgment, and ability to plan and organise can be observed. Patients may develop mood changes like depression, anxiety, irritability, and anger.

Creutzfeldt-Jakob disease

Creutzfeldt-Jakob disease (CJD) is a rare, degenerative brain disorder and the most common prion disease (or transmissible spongiform encephalopathies).

CJD is caused by the buildup of abnormal prion proteins in the brain. At least 85% of CJD cases are sporadic and about 5-10% of cases are hereditary. Infectious prions can occur due to variants in the PRNP gene. Variants in PRNP in sperm or egg cells are transmitted to the offspring. In the sporadic form, errors are more likely to occur with aging, which explains the general advanced age at onset of CJD and other prion diseases.

Symptoms usually occur at age 60, and about 70% of patients die within one year. CJD is characterised by rapidly progressive dementia. Initially, patients may experience memory impairment, behavioral changes, lack of coordination and visual disturbances. As the illness progresses, patient’s mental impairment becomes severe and involuntary muscle movements, blindness, weakness of extremities, and coma may occur. Pneumonia and other infections often occur which can lead to death.

Last updated: 09.09.2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases
  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA- and ISO15189 accredited, GMP- and ISO9001 and 13485 certified

Are you a patient?

Are you a physician?